Merryspring Medical raises nearly RMB 100M in Series B funding to pioneer COPD ablation therapy
Qiming Venture Partners
Healthcare Investment Institutions
TusPark Ventures
Investment Institutions in the Field of Technological Innovation
Recently, Merryspring Medical announced the completion of its Series B financing round. This round was led by Qiming Venture Partners, with participation from Lotus Lake Capital.
The raised funds will be used to accelerate the clinical promotion, domestic and international registration, and market expansion of its global-first "Real-time Electromagnetic Navigation-guided Bronchial Rheomorphic Plasty." This initiative aims to further drive innovation and advancement in interventional treatment technologies for Chronic Obstructive Pulmonary Disease (COPD).
According to World Health Organization (WHO) data, chronic obstructive pulmonary disease (COPD) ranks as the third leading cause of death globally. In 2024, China included COPD in its public health program management. However, existing drug therapies offer limited efficacy, leaving substantial unmet clinical needs.
Merryspring Medical's self-developed Breeze One® real-time electromagnetic navigation pulsed field ablation system received the "Breakthrough Device Designation" from the U.S. FDA in April 2025. This milestone marks a significant achievement for China's respiratory interventional therapy sector on the global stage.
The system features three core innovative advantages:
Integrated Real-time EM Navigation & Targeted Ablation
The system integrates 3D electromagnetic navigation technology, functioning like a "bronchial GPS" for physicians. It overcomes the visual limitations of traditional bronchoscopy, significantly shortens the clinical learning curve, and enhances procedural accuracy and efficiency. Simultaneously, its real-time ablation site mapping capability effectively prevents missed or repeated treatments, substantially improving procedural safety and consistency.
Addressing the Root Cause: Advancing COPD Toward "Clinical Cure"
By utilizing pulsed field technology to directly ablate abnormal mucus-secreting goblet cells, the system reduces sputum production at its source. This alleviates symptoms such as cough, sputum production, and dyspnea, shifting the treatment paradigm from symptomatic management to addressing the underlying pathology. The technology is characterized by high precision and strong tissue selectivity, achieving a "resurfacing" effect on the bronchial epithelium—clearing pathological tissue while preserving healthy structures and self-regeneration capacity.
Non-thermal Mechanism for Enhanced Safety
The system operates via a non-thermal physical mechanism, avoiding thermal or mechanical damage to adjacent normal tissues such as blood vessels, nerves, and cartilage. This fundamentally improves procedural safety.